Immuron CEO Steven Lydeamore presented at AusBioInvest
30 Outubro 2023 - 8:21AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company, is pleased to advise
our Chief Executive Officer, Steven Lydeamore, presented at
AusBioInvest 2023 on Monday, October 30th in the 9.40am – 10.35am
session (AEST) at the Park Hyatt, Melbourne, Australia.
A copy of the presentation being made at
AusBioInvest 2023 is available on the Company’s website.
https://www.immuron.com.au/corporate-presentations/
This release has been
authorised by the directors of Immuron Limited.
COMPANY
CONTACT:
Steven LydeamoreChief Executive
OfficerPh: +61 (0)3 9824 5254info@immuron.com
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercialising orally delivered
targeted polyclonal antibodies for the treatment of infectious
diseases.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Immuron (NASDAQ:IMRN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024